Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Akebia Therapeutics (AKBA) over the last 9 years, with Q3 2025 value amounting to $77000.0.

  • Akebia Therapeutics' Capital Expenditures rose 375000.0% to $77000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $223000.0, marking a year-over-year increase of 61935.48%. This contributed to the annual value of $33000.0 for FY2024, which is N/A changed from last year.
  • According to the latest figures from Q3 2025, Akebia Therapeutics' Capital Expenditures is $77000.0, which was up 375000.0% from $126000.0 recorded in Q2 2025.
  • Akebia Therapeutics' Capital Expenditures' 5-year high stood at $126000.0 during Q2 2025, with a 5-year trough of $2000.0 in Q3 2024.
  • For the 4-year period, Akebia Therapeutics' Capital Expenditures averaged around $53375.0, with its median value being $44000.0 (2021).
  • As far as peak fluctuations go, Akebia Therapeutics' Capital Expenditures soared by 9322.03% in 2022, and later skyrocketed by 375000.0% in 2025.
  • Quarter analysis of 4 years shows Akebia Therapeutics' Capital Expenditures stood at $59000.0 in 2021, then skyrocketed by 93.22% to $114000.0 in 2022, then plummeted by 98.25% to $2000.0 in 2024, then surged by 3750.0% to $77000.0 in 2025.
  • Its last three reported values are $77000.0 in Q3 2025, $126000.0 for Q2 2025, and $18000.0 during Q1 2025.